This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is AbbVie (ABBV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
Signs That Your Trading Will Ruin Your Retirement - July 08, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
6 Stocks to Wade Through the Spike in Coronavirus Cases
by Sreoshi Bera
The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.
Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - July 07, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
4 Value Stocks to Buy in a Recovering Economy
by Manaswita Ghosh Dutta
Vitals of financial markets and the U.S. economy are recovering gradually, making way for value stocks to gain pace ahead.
Top Ranked Value Stocks to Buy for July 7th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, July 7th
3 Diverse Stocks to Buy Now for Second Half Coronavirus Immunity & Growth
by Benjamin Rains
A look at three stocks from completely different economic sectors that are poised to grow during the second half of 2020, despite continued coronavirus economic uncertainty...
4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Johnson & Johnson Gets European Approval for Ebola Vaccine
by Zacks Equity Research
J&J (JNJ) gets approval from the European Commission for Ebola vaccine.
AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Powerful Proof Anyone Can Invest for an Early Retirement - July 02, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Ranked Income Stocks to Buy for July 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, July 2nd.
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
by Benjamin Rains
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
What Makes AbbVie (ABBV) a New Strong Buy Stock
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
by Benjamin Rains
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
Signs That Your Trading Will Ruin Your Retirement - June 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
5 Great Dividend Growth Stocks Amid Market Volatility
by Sweta Killa
The second wave of coronavirus infections has flared up volatility and made investors scurry for safety and regular income. This has resulted in higher appeal for dividend investing.
Novartis Gets Positive CHMP View for Cosentyx Label Expansion
by Zacks Equity Research
Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.
3 Top Dividend Stocks to Maximize Your Retirement Income - June 29, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Wall Street Braces for Higher Bouts of Volatility: 5 Safe Picks
by Tirthankar Chakraborty
As markets remain disturbed, investing in stocks that provide excellent risk-adjusted returns seems judicious. The best way to go about doing this is by creating a portfolio of low-beta stocks.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.